Emergent BioSolutions Inc.
EBS · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$190,600 | -$760,500 | -$211,600 | $230,900 |
| Dep. & Amort. | $108,800 | $125,100 | $143,300 | $123,800 |
| Deferred Tax | -$5,500 | -$8,900 | -$28,600 | $46,900 |
| Stock-Based Comp. | $18,000 | $23,100 | $45,100 | $42,400 |
| Change in WC | $88,700 | -$70,300 | -$2,100 | -$156,400 |
| Other Non-Cash | $39,300 | $485,200 | $19,800 | $33,500 |
| Operating Cash Flow | $58,700 | -$206,300 | -$34,100 | $321,100 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$22,900 | -$51,600 | -$115,800 | -$225,000 |
| Net Acquisitions | $0 | $270,200 | $0 | $0 |
| Inv. Purchases | $0 | $0 | $0 | $0 |
| Inv. Sales/Matur. | $0 | $0 | $0 | $0 |
| Other Inv. Act. | $148,100 | -$6,300 | -$265,500 | $0 |
| Investing Cash Flow | $125,200 | $212,300 | -$381,300 | -$225,000 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$198,400 | -$543,400 | $564,200 | -$35,900 |
| Stock Issued | $9,300 | $8,400 | $0 | $0 |
| Stock Repurch. | $0 | $0 | -$82,100 | -$106,000 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | -$900 | -$700 | -$900 | $900 |
| Financing Cash Flow | -$190,000 | -$535,700 | $481,200 | -$141,000 |
| Forex Effect | $0 | -$1,200 | $500 | -$300 |
| Net Chg. in Cash | -$6,100 | -$530,900 | $66,300 | -$45,200 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $111,700 | $642,600 | $576,300 | $621,500 |
| End Cash | $105,600 | $111,700 | $642,600 | $576,300 |
| Free Cash Flow | $35,800 | -$257,900 | -$149,900 | $96,100 |